Cardiology

Technology, such as continuous glucose monitors, changes the way patients are treated, but more work needs to be done for racial, ethnic, and socioeconomic disparities.

Pharmacists can help manage complications from long COVID-19, as no medications can treat it.

Patients with pulmonary arterial hypertension (PAH) received the maximum tolerated dose of background therapy with sotatercept or the placebo to the therapy.

The decision makes the RNAi therapeutic the only therapy approved by the FDA to treat ATTR-CM and hATTR-PN.

Heather Johnson, PharmD, BCACP, CTTS, and Heather Roth, BSPharm, RPh, discuss medications and devices used for improving cardiovascular health among patients with or without diabetes.

The new approval is an oral suspension for patients with hypertension and left ventricular hypertrophy and for the treatment of diabetic nephropathy.

Because of their accessibility in the community, pharmacists can help to deliver balanced and individualized services and address social determinants of health.

Currently, there is a gap in treatment for this patient population and intracerebral hemorrhagic stroke is considered an orphan disease.

Crystal Zhou, PharmD, APh, AHSCP, BCACP, joined Drug Topics to further discuss the Cut Hypertension Program and nontraditional roles within health care.

The study authors report that long-term daily administration of amlodipine induced behavioral changes in the rats during their open field test.

A program that includes peer coaching and monitoring tools can help pharmacists better manage hypertension in patients.

Currently, blood-thinning medications are only prescribed to patients who have already had a heart attack or stroke, as the drugs can cause serious bleeding.

Cardiovascular health is known to be associated with the probability of having active or developing migraine in the future.

Crystal Zhou, PharmD, APh, AHSCP, BCACP, discussed her role as Lead Pharmacist of the Cut Hypertension Program.

Tryvio was given FDA approval on March 19, 2024.

Poor cardiometabolic health is associated with cognitive impairment in later life, but there is no clear association between cardiometabolic trajectories and early markers.

The prevalence of high blood pressure is highest in Mississippi at 40.2% compared with the lowest in Colorado at 24.6%.

Ozempic is now the most broadly indicated glucagon-like peptide-1 receptor agonist across the pharmaceutical drug market.

Check out this list of our top 5 most read cardiology stories from the year 2024.

Kathryn Litten, PharmD, discussed the pharmacist’s role in helping patients manage metabolic dysfunction-associated steatotic liver disease.

John Bucheit, PharmD, joined Drug Topics to discuss statins and nonstatins’ efficacy in treating cardiovascular disease.

Patients with ASCVD experienced a more significant reduction in LDL-C.

This approval marks the availability of the first near-complete stabilizer of transthyretin.

Results of a study at the Veterans Health Administration found that feedback and education led to better medication outcomes for patients.

Study results are especially important for women, who are more likely to experience heart failure with mildly reduced or preserved ejection fraction.

A PDUFA date for acoramidis has been set for November 29, 2024.

High copayments can be a structural barrier to medication therapy adherence.

In a comprehensive literature review, researchers addressed the impact cardiac surgery has on gastrointestinal outcomes.

Pharmacists can screen for social determinants of health and patient beliefs about medications as a way to improve adherence and subsequent outcomes in heart failure.

Research presented at CHEST 2024 examined the effect of steroid choice on individuals who have a dual diagnosis of heart failure and COPD.